Amarantus BioScience Holdings, Inc. (AMBS)

Amarantus BioScience Holdings, Inc. (AMBS) Healthcare & Pipeline Overview

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company developing diagnostic and therapeutic product candidates in neurology, psychiatry, ophthalmology, and regenerative medicine. Its pipeline includes the LymPro test for Alzheimer's, MSPrecise for multiple sclerosis, Eltoprazine for Parkinson's, and Engineered Skin Substitute for severe burns, supported by strategic research agreements.

What Is the Investment Thesis for AMBS?

Amarantus BioScience Holdings, Inc. presents a research-stage biopharmaceutical profile characterized by a broad pipeline of diagnostic and therapeutic candidates across high-need areas like neurology, oncology, and regenerative medicine. The company's value drivers include the potential for its LymPro test in Alzheimer's diagnostics and MSPrecise for multiple sclerosis, addressing significant unmet needs in early disease detection. The therapeutic candidate Eltoprazine targets Parkinson's disease-related dyskinesia, a condition with limited treatment options. Furthermore, the Engineered Skin Substitute (ESS) is in mid-stage clinical development for severe burns, representing a tangible asset with a clearer path to market compared to earlier-stage assets. Strategic cooperative research and development agreements with institutions like the U.S. Army Institute of Surgical Research and Rutgers University provide external validation and resource leverage for its R&D efforts. However, the company operates with a significantly negative profit margin of -4995.2% and a market capitalization of 37K, indicative of a pre-revenue, high-burn-rate development stage typical for early-stage biotechnology firms. The high beta of -12.34 also signals extreme volatility or data anomalies often associated with thinly traded OTC securities. Future value creation is heavily dependent on successful clinical trial outcomes, regulatory approvals, and subsequent commercialization, which are inherently high-risk propositions.

Based on FMP financials and quantitative analysis

AMBS Key Highlights

• Market Capitalization stands at $0.00B, indicating a micro-cap or pre-commercial stage enterprise with limited public market valuation.
• Profit Margin is significantly negative at -4995.2%, reflecting substantial operating losses typical for a biopharmaceutical company in the research and development phase with no commercialized products generating revenue.
• Gross Margin is 100.0%, which is characteristic of a company primarily engaged in R&D activities, where direct costs of goods sold are not yet incurred or are negligible relative to overall expenses.
• Beta is reported at -12.34, an exceptionally high negative value suggesting an inverse relationship with market movements, which could be attributed to low trading volume, specific company-centric news, or data anomalies common in thinly traded OTC securities.
• Dividend Yield is None, consistent with a growth-oriented biotechnology company that reinvests all available capital into research and development rather than distributing profits to shareholders.

Who Are AMBS's Competitors?

AMBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AMBS's Key Strengths?

• Diverse pipeline of diagnostic and therapeutic candidates addressing multiple high-need medical areas.
• Proprietary diagnostic platforms (LymPro, MSPrecise) and therapeutic candidates (Eltoprazine, ESS).
• Mid-stage clinical development product (ESS) offers a more advanced asset with potential for near-term milestones.
• Strategic cooperative research and development agreements with reputable institutions (U.S. Army, Rutgers University).

What Are AMBS's Weaknesses?

• Significantly negative profit margin (-4995.2%) indicates substantial operating losses and high cash burn.
• Market capitalization of 37K suggests a very early-stage or distressed valuation, limiting access to capital.
• All products are in development, meaning no current revenue generation and high dependence on future clinical success and regulatory approvals.
• Trading on the OTC market, which typically entails lower liquidity and less stringent disclosure requirements.

What Could Drive AMBS Stock Higher?

• Advancement of the Engineered Skin Substitute (ESS) through its mid-stage clinical development, with potential for further clinical trial data releases or progression to later stages.
• Publication of additional preclinical or clinical data for the LymPro test for Alzheimer's disease or MSPrecise for multiple sclerosis, which could validate their diagnostic utility.
• Progression of Eltoprazine into later-stage clinical trials for Parkinson's disease Levadopa-Induced Dyskinesia or ADHD, indicating positive early-stage results.
• Continued development and expansion of the NuroPro, BC-SeraPro, and PhenoGuard diagnostic and discovery platforms, potentially leading to new product candidates or intellectual property.
• Further developments or expansions of cooperative research and development agreements with the U.S. Army Institute of Surgical Research and Rutgers University, potentially leading to new funding or research initiatives.

What Are the Key Risks for AMBS?

• Financial-distress signal — its Altman Z-Score of -19.27 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• High clinical trial failure rates inherent in biopharmaceutical development, particularly for early-stage assets, could prevent any product from reaching commercialization.
• Significant capital requirements and a negative profit margin indicate a continuous need for financing, potentially leading to substantial shareholder dilution through equity raises.
• Intense competition from larger, well-established pharmaceutical and biotechnology companies with greater financial resources and more advanced pipelines could limit market penetration.
• Regulatory hurdles and lengthy approval processes for diagnostic tests and therapeutic drugs pose significant challenges and can delay or prevent market entry.
• The 'Unknown' disclosure status and 'OTC Other' trading tier present risks of limited transparency, low liquidity, and extreme price volatility, making investment highly speculative.

What Are the Growth Opportunities for AMBS?

• Growth opportunity 1: The LymPro test for Alzheimer's disease represents a significant growth opportunity. Alzheimer's is a devastating neurodegenerative disease with an urgent need for early and accurate diagnosis. A simple blood test like LymPro, if successfully developed and commercialized, could revolutionize early detection, enabling earlier intervention and better disease management. The global Alzheimer's disease diagnostics market is projected to grow substantially, driven by an aging population and increasing awareness. Amarantus's proprietary nature of this test could provide a strong competitive advantage, potentially capturing a meaningful share of this market upon regulatory approval and widespread adoption, with a timeline dependent on clinical validation and regulatory pathways.
• Growth opportunity 2: MSPrecise, a proprietary DNA sequencing assay for multiple sclerosis identification, addresses another critical diagnostic need. Multiple sclerosis is a complex autoimmune disease, and early, precise diagnosis is crucial for effective treatment. A DNA sequencing-based diagnostic offers the potential for high accuracy and specificity, which could differentiate it from existing diagnostic methods. The market for MS diagnostics is expanding, fueled by advancements in genetic testing and personalized medicine. Successful development and market penetration of MSPrecise could position Amarantus as a key player in this niche, offering a valuable tool for neurologists and patients, with commercialization timelines tied to clinical trials and regulatory clearances.
• Growth opportunity 3: Eltoprazine, a small molecule drug for Parkinson's disease Levadopa-Induced Dyskinesia (PD-LID) and attention deficit hyperactivity disorders (ADHD), targets areas with significant patient populations and unmet needs. PD-LID is a debilitating side effect of long-term levodopa therapy, impacting the quality of life for many Parkinson's patients. A novel therapeutic like Eltoprazine could offer a much-needed treatment option. The global market for Parkinson's disease therapeutics is substantial and growing, as is the market for ADHD treatments. Advancing Eltoprazine through clinical trials and securing regulatory approval could unlock considerable revenue potential for Amarantus, with market entry dependent on successful Phase 2 and 3 studies.
• Growth opportunity 4: The Engineered Skin Substitute (ESS) is a cell therapy-based autologous skin replacement product in mid-stage clinical development for severe burns. This represents a high-impact growth opportunity in regenerative medicine. Severe burns are life-threatening injuries requiring complex and often inadequate treatment options. An autologous (patient's own cells) skin replacement product minimizes rejection risks and could significantly improve outcomes for burn victims. The market for advanced wound care and regenerative skin substitutes is growing, driven by an increasing incidence of burns and chronic wounds. Successful completion of mid-stage and late-stage clinical trials for ESS could position Amarantus to address a critical medical need with a potentially transformative product, offering a clear path to commercialization within the next few years, assuming positive trial results.
• Growth opportunity 5: Amarantus's suite of diagnostic platforms, including NuroPro for neurodegenerative diseases, BC-SeraPro for breast cancer, and PhenoGuard for neurotrophic factor discovery, represents a foundational growth opportunity. These platforms offer the potential for developing multiple diagnostic and therapeutic candidates beyond the current pipeline. For instance, NuroPro's application in Parkinson's disease could be expanded to other neurodegenerative conditions, while BC-SeraPro could identify novel biomarkers for various cancers. The PhenoGuard platform's ability to discover new neurotrophic factors could lead to entirely new therapeutic programs. These platforms provide a scalable approach to R&D, potentially generating a continuous stream of new product candidates and intellectual property, with long-term revenue potential as new assays and therapies emerge from these foundational technologies.

What Opportunities Does AMBS Have?

• Successful clinical trials and regulatory approval of LymPro or MSPrecise could address significant unmet diagnostic needs.
• Advancement and commercialization of the Engineered Skin Substitute (ESS) could capture a share of the growing regenerative medicine market.
• Expansion of platform technologies (NuroPro, BC-SeraPro, PhenoGuard) to generate new diagnostic or therapeutic candidates.
• Potential for strategic partnerships or licensing deals with larger pharmaceutical companies for pipeline assets.

What Threats Does AMBS Face?

• High failure rates inherent in biopharmaceutical clinical development and regulatory processes.
• Intense competition from larger, well-funded pharmaceutical and biotechnology companies.
• Significant capital requirements for R&D, with ongoing risk of dilution from equity financing.
• Market acceptance and reimbursement challenges even if products achieve regulatory approval.
• Volatility and liquidity risks associated with trading on the OTC market.

What Are AMBS's Competitive Advantages?

• Proprietary diagnostic technologies such as the LymPro test for Alzheimer's and MSPrecise DNA sequencing assay for multiple sclerosis.
• Exclusive development rights to therapeutic candidates like Eltoprazine for Parkinson's disease-related dyskinesia.
• Advanced cell therapy platform for Engineered Skin Substitute (ESS) in mid-stage clinical development for severe burns.
• Specialized diagnostic and discovery platforms including NuroPro, BC-SeraPro, and PhenoGuard, which can generate future product candidates.
• Cooperative research and development agreements with institutions like the U.S. Army Institute of Surgical Research and Rutgers University, providing access to expertise and resources.

What Does AMBS Do?

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company established in 2008 and headquartered in New York, New York. The company's strategic focus lies in the development of diagnostic and therapeutic product candidates across several critical medical areas, including neurology, psychiatry, ophthalmology, and regenerative medicine. Initially known as Amarantus Bioscience, Inc., the company rebranded to Amarantus BioScience Holdings, Inc. in April 2013, reflecting its evolving corporate structure and broader ambitions within the life sciences sector. Its diagnostic portfolio in development features the lymphocyte proliferation (LymPro) test, a blood-based diagnostic designed for Alzheimer's disease, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying patients with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug candidate for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders. Another key therapeutic asset is the mesencephalic-astrocyte-derived neurotrophic factor, which is being investigated for its potential in treating various animal models of conditions such as retinitis pigmentosa and retinal artery occlusion. Beyond specific product candidates, the company has also developed several platform technologies, including NuroPro for neurodegenerative disease diagnostics with applications in Parkinson's disease, BC-SeraPro for oncology diagnostics targeting breast cancer, and the PhenoGuard platform for neurotrophic factor discovery. A significant mid-stage clinical development program is the Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product intended for life-threatening severe burns. Amarantus BioScience Holdings, Inc. further strengthens its research and development capabilities through a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University, underscoring its commitment to collaborative innovation in addressing unmet medical needs.

What Products and Services Does AMBS Offer?

• Develop diagnostic blood tests for neurological conditions like Alzheimer's disease (LymPro test).
• Create proprietary DNA sequencing assays for identifying patients with multiple sclerosis (MSPrecise).
• Research and develop small molecule drugs for neurological disorders, such as Eltoprazine for Parkinson's disease Levadopa-Induced Dyskinesia.
• Investigate neurotrophic factors for treating ophthalmological conditions like retinitis pigmentosa and retinal artery occlusion.
• Develop neurodegenerative disease diagnostic platforms (NuroPro) and oncology diagnostic platforms (BC-SeraPro).
• Advance a neurotrophic factor discovery platform (PhenoGuard).
• Develop cell therapy-based autologous skin replacement products for severe burns (Engineered Skin Substitute - ESS).
• Engage in cooperative research and development agreements with academic and governmental institutions.

How Does AMBS Make Money?

• Focuses on research and development of novel diagnostic and therapeutic candidates across multiple disease areas.
• Aims to generate revenue through the eventual commercialization and sales of approved diagnostic tests and pharmaceutical products.
• Potentially seeks licensing agreements or partnerships for its proprietary platforms and drug candidates to fund development and access broader markets.
• Relies on capital raises and strategic agreements to finance its extensive R&D pipeline, given its pre-revenue stage.
• Builds intellectual property through patents on its diagnostic assays, drug compounds, and cell therapies.

What Industry Does AMBS Operate In?

Amarantus BioScience Holdings, Inc. operates within the dynamic and highly specialized Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. Key market trends include increasing demand for precision diagnostics, novel therapies for neurodegenerative diseases, and advancements in regenerative medicine. Amarantus's focus on diagnostics for Alzheimer's and multiple sclerosis positions it within a growing segment addressing early detection and personalized medicine. Its therapeutic pipeline, including Eltoprazine for Parkinson's and ESS for severe burns, targets areas with substantial unmet medical needs and large potential market sizes. The competitive landscape is intense, with numerous established pharmaceutical giants and emerging biotech firms vying for market share. Success in this industry is heavily reliant on intellectual property, clinical trial outcomes, and strategic partnerships. Amarantus's cooperative research agreements provide a competitive edge in resource utilization and scientific validation, but it faces competition from companies with more advanced pipelines and greater financial resources.

Who Are AMBS's Key Customers?

• Healthcare providers and clinicians seeking advanced diagnostic tools for neurological and psychiatric conditions.
• Patients suffering from neurodegenerative diseases like Alzheimer's and Parkinson's, and autoimmune diseases like multiple sclerosis.
• Hospitals and burn centers requiring advanced regenerative medicine solutions for severe burn treatment.
• Pharmaceutical companies potentially interested in licensing or acquiring Amarantus's drug candidates or diagnostic platforms.
• Research institutions and academic partners collaborating on scientific discovery and product development.

How Amarantus BioScience Holdings, Inc. Is Valued

Amarantus BioScience Holdings, Inc. carries a market capitalization of 37K, placing it in the micro-cap category. Relative to its peer group, AMBS's quantitative score of 52/100 is below the peer average of 76/100.

Company Profile

Amarantus BioScience Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO John Wesley Commissiong. AMBS has traded publicly since 2010.

ROE 21%Key Financial Metrics

Return on equity for Amarantus BioScience Holdings, Inc. stands at 21.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.7%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.

F-Score 3/9Financial Health

Amarantus BioScience Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.27 places it in the distress zone, a signal of elevated financial risk.

AMBS Financials

AMBS Latest News

AMBS Analyst Consensus

AMBS MoonshotScore

What Investors Ask About Amarantus BioScience Holdings, Inc. (AMBS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources